REGENTIS BIOMATERIALS LTD.
Regentis Biomaterials is a regenerative medicine company developing tissue repair solutions, with current efforts focused on orthopedic treatments. Its Gelrin platform uses degradable hydrogel implants made from polyethylene glycol diacrylate and denatured fibrinogen. The lead product, GelrinC, is a cell-free, off-the-shelf hydrogel cured into an implant to treat painful injuries to articular knee cartilage. It is approved as a medical device with a CE mark in Europe and is being evaluated in a pivotal clinical trial in the United States and Europe. Regentis also has pipeline products GelrinP, a paste intended for injuries in smaller joints, and GelrinV, an injectable gel intended for moderate osteoarthritis. Regentis plans to seek strategic partners to bring GelrinC to market in Europe and intends to market it in the United States with a strategic partner if it receives approval for commercial sale. The company is building on the Gelrin platform for additional tissue regeneration applications. Its principal office is in Herzliya, Israel.
No SEC Form 4 filings for $RGNT in the last 30 days.
See all $RGNT insider activity →Regentis Biomaterials (RGNT) signed a 4-year deal for GelrinC in Israel, expecting revenue from 2027. This follows their efforts in Europe and a Phase 3 trial in the U.S. Revenue timing and U.S. trial progress are key developments.
Regentis Biomaterials (RGNT) reported strong interest in GelrinC, its CE Mark-approved knee cartilage repair implant, at the ICRS Summit. The company highlighted GelrinC's clinical results, ease of use, and potential to address a significant unmet need. Regentis is focused on expanding clinical adoption in Europe and advancing its U.S. FDA pivotal trial.
Regentis Biomaterials (RGNT) is developing GelrinC, a hydrogel implant for knee cartilage repair. Phase II data showed 100% greater improvement than microfracture at two years. GelrinC has CE Mark approval in Europe, with U.S. trial completion targeted for late 2026. The company aims to position itself as a key player in the evolving cartilage repair market, potentially delaying or preventing knee replacements.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning RGNT (REGENTIS BIOMATERIALS LTD.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent RGNT coverage spans financial news, technology and earnings.
The deal adds a new revenue stream but will not affect cash flow until 2027.
Positive sentiment for GelrinC commercialization momentum, but it is not a new clinical datapoint or regulatory milestone.
Positive Phase II results and regulatory clearance suggest strong upside potential.
Positive trial progress may boost RGNT share price as investors anticipate regulatory approval.
The new earnings and capital raise provide fresh data on cash position and trial progress, potentially influencing short‑term price volatility.
AlphAI scores every news story that mentions RGNT with an AI model for sentiment and relevance, and aggregates insider trades from REGENTIS BIOMATERIALS LTD.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Regentis Biomaterials (RGNT) signed a 4-year deal for GelrinC in Israel, expecting revenue from 2027. This follows their efforts in Europe and a Phase 3 trial in the U.S. Revenue timing and U.S. trial progress are key developments.
Regentis Biomaterials (RGNT) reported strong interest in GelrinC, its CE Mark-approved knee cartilage repair implant, at the ICRS Summit. The company highlighted GelrinC's clinical results, ease of use, and potential to address a significant unmet need. Regentis is focused on expanding clinical adoption in Europe and advancing its U.S. FDA pivotal trial.
Regentis Biomaterials (RGNT) is developing GelrinC, a hydrogel implant for knee cartilage repair. Phase II data showed 100% greater improvement than microfracture at two years. GelrinC has CE Mark approval in Europe, with U.S. trial completion targeted for late 2026. The company aims to position itself as a key player in the evolving cartilage repair market, potentially delaying or preventing knee replacements.
Regentis Biomaterials (RGNT) is developing GelrinC, a treatment for knee cartilage repair. The product has early clinical support and European approval, with a U.S. trial ongoing. Researchers at Duke University and Mayo Clinic are also exploring cartilage regeneration. GelrinC aims to support natural cartilage repair, addressing a challenging medical issue.
Regentis Biomaterials (NYSE American:RGNT) reported H1 2026 results, highlighting progress in GelrinC U.S. trial with 43 patients treated and enrollment expected to complete by year-end. The company expanded European commercialization efforts and improved production yield by 400%. Regentis raised $6.5M in a private placement, with cash reserves of $9M as of June 30, 2026. H1 2026 net loss was $2.6M, an improvement from the same period in 2025.
REGENTIS BIOMATERIALS LTD. (RGNT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026 Expands European commercialization readiness,
Regentis Biomaterials (NYSE American: RGNT) priced a $6.5 million private placement with accredited and institutional investors at $3.50 per ordinary share, plus accompanying warrants (or $3.4999 per pre-funded warrant). The company will issue 1,857,143 shares (or pre-funded warrants) and warrants to buy 1,857,143 shares. Pre-funded warrants are exercisable at $0.0001; ordinary warrants at $4.20 for five years. Net proceeds will fund its GelrinC pivotal trial, FDA pre-market approval preparation
Regentis Biomaterials (NYSE: RGNT) shares moved sharply after the company filed a Form 6-K with the SEC, saying it requested withdrawal of its Form F-1 registration statement and decided not to pursue the related public offering. The stock rose 506.45% to $9.40 intraday, then fell 9.15% to $8.54 in after-hours.
Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.
Regentis Biomaterials (NYSE: RGNT) has filed an F-1 registration statement to sell 3,333,334 Ordinary Shares at an assumed public offering price of $3.00 per share. The company is developing GelrinC, a regenerative medicine product for articular knee cartilage repair, which is currently undergoing a pivotal clinical trial. Regentis aims to use the net proceeds from this offering for further clinical development of GelrinC, research and development activities, operational readiness, and European market entry.
